



## Research Paper

# Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates reveals the emergence of *bla*<sub>OXA-23</sub> and *bla*<sub>NDM-1</sub> encoding international clones in India

Sunil Kumar<sup>a,b,1</sup>, Prashant P. Patil<sup>c,1,2</sup>, Lipika Singhal<sup>d</sup>, Pallab Ray<sup>a</sup>, Prabhu B. Patil<sup>c,\*</sup>, Vikas Gautam<sup>a,\*</sup>

<sup>a</sup> Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India

<sup>b</sup> Department of Biotechnology, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, Haryana 133207, India

<sup>c</sup> Bacterial Genomics and Evolution Laboratory, CSIR-Institute of Microbial Technology, Sector - 39A, Chandigarh 160036, India

<sup>d</sup> Government Medical College and Hospital, Sector -32B, Chandigarh 160030, India

## ARTICLE INFO

## Keywords:

Carbapenem resistance  
*Acinetobacter baumannii*  
 International clones  
 Multilocus sequence typing  
*bla*<sub>OXA-23</sub>-like  
 And *bla*<sub>NDM-1</sub>

## ABSTRACT

*Acinetobacter baumannii* is a nosocomial pathogen increasingly affecting the critically ill patients and represents a major public health challenge. Carbapenem-resistant *A. baumannii* (CRAB) is found to be associated with International Clones (ICs) and different classes of carbapenemases. The objective of the present study was to investigate the prevalence of carbapenem resistance genes, clonal relationship and genetic structure of clinical isolates of *A. baumannii*. In the present study, multi-locus sequence typing (MLST<sup>OX</sup>) and analysis were carried out using Oxford scheme for 86 clinical isolates of CRAB along with 11 carbapenem sensitive *A. baumannii* (CSAB) collected over a period of two years (2014–2016) from two tertiary care hospitals of North India. We observed a high prevalence of the *bla*<sub>OXA-23</sub>-like (97.7%) among the CRAB followed by *bla*<sub>NDM-1</sub> (29.1%) and *bla*<sub>OXA58</sub>-like (3.5%). Forty-seven Sequence Types (STs) were represented by all 97 isolates, out of which, 28 (59.6%) were novel STs that were assigned to 41 isolates. STs 451 (13%), 447 (7%), 195 (6%) and 848 (5%) were the most common STs. The majority of CRAB isolates (44.3%) belonged to the CC92, followed by the CC447 (15.1%), CC109 (9.3%) and CC110 (3.4%), which corresponds to the IC2, 8, 1 and 7 respectively. Phylogenetic and recombination analysis suggested two major and one minor lineage in the population. Further linkage disequilibrium analysis suggested clonal nature of the population as recombination was noticed at a low frequency, which was not enough to split the clonal relationship. The knowledge of genetic structure of CRAB from this study will be invaluable to illustrate epidemiology, surveillance and understanding its global diversity.

## 1. Introduction

*Acinetobacter baumannii* is a nosocomial pathogen of clinical significance, which has been implicated in a wide spectrum of hospital-acquired infections, mostly among immunocompromised patients in intensive care units (Dijkshoorn et al., 2007; Howard et al., 2012; Peleg et al., 2008; Perez et al., 2007). Infections caused by carbapenem-resistant *A. baumannii* (CRAB) have become difficult to manage and are often associated with high morbidity and mortality (Doi et al., 2009; Peleg et al., 2007a). *A. baumannii* has the ability to acquire antibiotic resistance determinants, cause hospital outbreak leading to global dissemination of clones (Dijkshoorn et al., 2007). The emergence of such

highly successful clones is leading to the increasing global occurrence of *A. baumannii* infections (Diancourt et al., 2010).

Carbapenems have good antibacterial activity against *A. baumannii*. Carbapenems are not the first choice antibiotic to treat *A. baumannii* infections, they are in fact one of the last resort treatments (Peleg et al., 2008). However, the emergence of resistance to carbapenem was first reported in 1993 (Paton et al., 1993) followed by similar reports from India and different parts of the world (Lee et al., 2007; Peleg et al., 2007b; Tiwari et al., 2012). Interestingly, several resistance islands have recently been identified among Multidrug-resistant (MDR) isolates of *A. baumannii*, which belong either to IC1 or IC2 (Adams et al., 2008; Fournier et al., 2006; Nigro and Hall, 2012). Carbapenem resistance in

\* Corresponding authors.

E-mail addresses: [pbpatil@imtech.res.in](mailto:pbpatil@imtech.res.in) (P.B. Patil), [r\\_vg@yahoo.co.uk](mailto:r_vg@yahoo.co.uk) (V. Gautam).

<sup>1</sup> These authors contributed equally to this work.

<sup>2</sup> Present Address: Department of Microbiology, University of Washington, School of Medicine, Seattle, Washington, USA.

*A. baumannii* is mainly mediated by the production of carbapenem-hydrolyzing enzymes (Peleg et al., 2008; Tiwari et al., 2012). Genes encoding a variety of carbapenem-hydrolyzing beta-lactamases have been detected in *A. baumannii* that belong to class B (*bla*<sub>IMP-1</sub>, *bla*<sub>VIM-2</sub>, *bla*<sub>SIM-1</sub> & *bla*<sub>NDM</sub>) and class D (*bla*<sub>OXA-23</sub>-like, *bla*<sub>OXA-24</sub>-like or *bla*<sub>OXA-40</sub>-like, *bla*<sub>OXA-51</sub>-like, *bla*<sub>OXA-58</sub>-like, *bla*<sub>OXA-143</sub>-like & *bla*<sub>OXA-235</sub>-like) (Poirel et al., 2010; Poirel and Nordmann, 2006; Robledo et al., 2010; Robledo et al., 2011). The class D OXA-type carbapenemases are by far the most prevalent carbapenemases in *A. baumannii* (Poirel and Nordmann, 2006). The *bla*<sub>OXA-23</sub>-like seems to be the most prevalent among CRAB isolates (Rafei et al., 2015). There is a report of newly found carbapenemase in *Acinetobacter* spp., which includes Tripoli metallo-beta-lactamase 1 (TMB-1) (Kayama et al., 2014). Therapy for infection due to CRAB often requires treatment by colistin methanesulfonate (CMS). However, there are reports on *A. baumannii* showing resistance to almost all the currently available antibiotics including colistin (Magiorakos et al., 2012; Nurtop et al., 2019).

Several molecular methods like Multi-locus sequence typing (MLST) (Bartual et al., 2005), Pulsed-field gel electrophoresis (PFGE) (Hamouda et al., 2010), rep-PCR (Grisold et al., 2010), multi-locus variable-number tandem-repeat (VNTR) analysis (MLVA) (Pourcel et al., 2011; Turton et al., 2009) have been used to type *A. baumannii* strains. MLST is a widely used method for typing of the pathogens, which is based on sequence analysis of loci from housekeeping genes. MLST has several advantages over the other typing methods. Apart from resolution, MLST provides unambiguous typing data to exchange and compare results among laboratories, which make it an ideal typing method for an epidemiological study (Bartual et al., 2005; Hamouda et al., 2010).

In this study, genetic and epidemiological relatedness of clinical isolates of CRAB & CSAB were carried out using MLST<sup>OX</sup> analysis. To the best of our knowledge, only two studies have investigated the molecular epidemiological characteristics of CRAB in India but these studies restricted to typing of a limited number of isolates (Rynga et al., 2013; Saranathan et al., 2015). However, a large number of clinical isolates of *A. baumannii* are included in this study from two hospitals of North India. We also studied the prevalence of different carbapenemases and clonal nature of the population under study.

## 2. Materials and methods

### 2.1. *A. baumannii* isolate collection

A total of 161 isolates of *A. baumannii* were collected and the study was carried out with those that were found to be carbapenem resistant ( $n = 86$ ) and susceptible ( $n = 11$ ). A total of 75 isolates of *A. baumannii* (94% carbapenem resistant) were consecutively isolated from March to June 2014. In addition, 7 & 15 isolates were included from the year 2013 and 2016 respectively. These isolates were recovered from the patients admitted to Nehru Hospital, PGIMER, and Government Medical College & Hospital Chandigarh, India. We have included only one isolate per patient in this study. These isolates were recovered from blood ( $n = 55$ ), cerebrospinal fluid (CSF) ( $n = 20$ ), body fluid ( $n = 14$ ), pus ( $n = 4$ ) and respiratory specimens ( $n = 4$ ) (S1 Table). Patient's informed consent was not required as it was a part of routine clinical testing. These isolates were identified as *A. baumannii* by using MALDI-TOF MS followed by PCR of *gyrB* & *bla*<sub>OXA-51</sub>-like genes (Brown et al., 2005; Higgins et al., 2007). Genomic DNA was extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as per user manual and used for subsequent tests.

### 2.2. Antimicrobial susceptibility testing

All isolates were tested by Kirby Bauer Disk diffusion method for imipenem, meropenem, doripenem (Becton Dickinson, Franklin Lakes, New Jersey, USA), chloramphenicol, amikacin, ceftazidime, cefepime,

cefotaxime, piperacillin/tazobactam, ciprofloxacin & gentamicin (HiMedia Laboratories GmbH, Germany) using updated breakpoints of the Clinical and Laboratory Standards Institute (CLSI) (<http://www.clsi.org>). MICs for imipenem, meropenem and doripenem (Sigma Aldrich, St. Louis, Missouri, USA) were also determined for *A. baumannii* isolates by agar dilution method on Mueller-Hinton agar according to the CLSI guidelines. CRAB isolate was defined as an isolate, which was resistant to both imipenem and meropenem (i.e., MIC  $\geq 8$   $\mu\text{g/ml}$ ) (Chen et al., 2017).

### 2.3. PCR based screening for carbapenemase genes

Intrinsic carbapenemase encoding gene in *A. baumannii* *bla*<sub>OXA-51</sub>-like was detected using previously standardized PCR primer (Higgins et al., 2007). Major groups of beta-lactamases were screened using PCR, which confer resistance to carbapenems. These included *bla*<sub>OXA-23</sub>-like, *bla*<sub>OXA-24</sub>-like (40-type), *bla*<sub>OXA-58</sub>-like, class-B beta-lactamases, i.e. *bla*<sub>IMP-1</sub>, *bla*<sub>SIM-1</sub>, *bla*<sub>NDM-1</sub> and class-C beta-lactamases, i.e. *bla*<sub>ampC</sub>. The primers used in the screening of the carbapenemase gene are listed in the S2 Table. PCR was carried out using PCR master mix (Sigma Aldrich, St. Louis, Missouri, United States) in the 'Veriti' thermal cycler (Applied Biosystems, Foster City, California, USA).

### 2.4. Multi-locus sequence typing

All isolates were subjected to MLST by PCR amplification and sequencing of seven housekeeping genes (*gltA*, *gdhB*, *gyrB*, *recA*, *gpi*, *cpn60*, and *rpoD*) as described by Oxford scheme introduced by Bartual et al., 2005 (Bartual et al., 2005). PCR amplification was carried out in 25  $\mu\text{l}$  reaction mixture volume containing 2 mM MgCl<sub>2</sub>, 20 mM Tris-HCl, 50 mM KCl, 250  $\mu\text{M}$  of each dNTP, 0.5  $\mu\text{M}$  of each primer and 2 U of Taq polymerase (Sigma Aldrich, St. Louis, Missouri, United States). The amplified product was resolved on 1.2% agarose gel and purified by using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Nucleotide sequences were determined using sequencing primers with the BigDye Terminator ready reaction mix, version 3.1 (Applied Biosystems, Waltham, MA.) as per standard sequencing conditions in accordance with the manufacturer's protocol. The reaction products were further separated and detected on an ABI PRISM genetic analyzer 3100 (Applied Biosystems, Waltham, MA). The sequences from both strands of each of seven loci of the same isolate were aligned separately, trimmed to the desired length and edited using SeqMan II program from the Lasergene software package (DNASTAR, Inc., Madison, WI). Sequence types (ST), allele profiles and clonal complexes were assigned by PubMLST database ([www.pubmlst.org/abaumannii/](http://www.pubmlst.org/abaumannii/)). New allele numbers and STs were assigned to unique alleles and STs from this study.

### 2.5. Genetic diversity and selection analysis

The DnaSP Version 5.10 (Librado and Rozas, 2009) was used for assessing sequence diversity by using concatenating sequences of the seven MLST housekeeping gene loci to calculate the number of polymorphic sites, nucleotide diversity ( $\pi$ ) as the average number of nucleotide differences per site between two sequences and average GC content. The  $\pi$  index is determined for each of the MLST loci for identifying the loci having the greatest diversity. The average non-synonymous/synonymous substitution rate ratios (dN/dS) were calculated by using MEGA version 6.06 (Tamura et al., 2013) to infer about the positive and purifying selection.

### 2.6. Population structure analysis

The eBURSTv3 (Feil et al., 2004) was used to assign the STs generated in this study to the clonal complex. The eBURSTv3 is based on a model of bacterial evolution, in which a particular ancestor founder ST

undergoes diversification to produce a subset of closely related STs and available at <http://eburst.mlst.net/>. Global optimal eBURST (goeBURST) (Francisco et al., 2009) was used to cluster the STs generated in this study with the existing STs in the global MLST database at single locus variants limitation, which generate the minimal spanning tree to visualize the possible evolutionary relationship between STs. The maximum likelihood (ML) method was used to generate the phylogenetic trees of strains or the STs with 1000 bootstrap replications. The split network of the STs was generated by the neighbor-net methods (Bryant and Moulton, 2004) using SplitsTree4 (Huson and Bryant, 2005).

### 2.7. Recombination and linkage disequilibrium analysis

The pairwise homoplasy index (*phi*) test (Bruen et al., 2006) implemented in SplitTree4 (Huson and Bryant, 2005) was used to detect the possibility of recombination among seven individual loci, all STs and STs belonging to different lineages. The *phi* test is a simple statistical test based on the pattern of nucleotide polymorphisms in the sequence alignment. If it is not consistent with the model of clonal population structure, the *phi* test gives the signal for recombination (*p*-value < .05). LDhat program (Auton and McVean, 2007) used in Recombination Detection Program (RDP) v.4.66 (Martin et al., 2015) was implemented to calculate mean per site  $\rho/\theta$  ratio based on the concatenated sequences of seven loci with 1,000,000 MCMC updates. The parameters  $\rho$  and  $\theta$  symbolized the rate of recombination and mutation respectively. Linkage disequilibrium from allelic data was analyzed by calculating the standardized index of association ( $I_A^S$ ) using LIAN v3.7 (Haubold and Hudson, 2000) ([http://adenine.biz.fh-weihenstephan.de/lian\\_3.1/](http://adenine.biz.fh-weihenstephan.de/lian_3.1/)). The  $I_A^S$  is a measure of clonality among the population and calculated using the Monte Carlo methods to test the null hypothesis of complete linkage equilibrium with 10,000 iterations on the allelic profile. For completely clonal population structure, alleles would be in completely disequilibrium and value for  $I_A^S > 0$ . SplitTree4 (Huson and Bryant, 2005) and the neighbor-net method (Bryant and Moulton, 2004) were used to generate a split network of seven individual loci.

## 3. Results

### 3.1. Antimicrobial susceptibility testing

Bacterial isolates were identified as *A. baumannii* using MALDI-TOF-MS, *bla*<sub>OXA-51</sub>-like and *gyrB* PCR after initial collection in the clinical bacteriology laboratory. Among them 86 isolates were found to be resistant to three carbapenems including imipenem, meropenem, and doripenem as MIC was  $\geq 16 \mu\text{g/ml}$  for all three carbapenems. Along with the three carbapenems, all 86 CRAB were also resistant to cefepime, cefotaxime, ceftazidime ciprofloxacin, and piperacillin-tazobactam.

### 3.2. Screening for carbapenemase genes

All 86 CRAB and 11 CSAB isolates (S1 Table) were screened for the presence of beta-lactamases genes. The major carbapenemase gene *bla*<sub>OXA-23</sub>-like was detected in 84/86 CRAB isolates (97.7%). Interestingly, 25 isolates (29.1%) and 3 isolates (3.5%) were positive for the *bla*<sub>NDM-1</sub> and *bla*<sub>OXA-58</sub>-like respectively (Table 1). Other beta-lactamase genes including *bla*<sub>SIM-1</sub>, *bla*<sub>IMP-1</sub> and *bla*<sub>OXA-24</sub>-like were undetectable in all the isolates under study (Table 1).

### 3.3. MLST and population structure analysis

All 97 (86 CRAB and 11 CSAB) isolates were subjected to typing using Oxford Bartual scheme of MLST. 47 STs were identified among 97 isolates under study. The most common ST was ST 451 represented by

**Table 1**  
Prevalence of  $\beta$ -lactamases among CRAB and CSAB isolates.

S. No.	$\beta$ -Lactamase genes	No. of isolates	Percentage
1	<i>bla</i> <sub>OXA-58</sub> -like	03	3.5% (CRAB)
2	<i>bla</i> <sub>OXA-23</sub> -like	84	97.7% (CRAB)
3	<i>bla</i> <sub>OXA-24</sub> -like	0	0
4	<i>bla</i> <sub>SIM-1</sub>	0	0
5	<i>bla</i> <sub>IMP-1</sub>	0	0
6	<i>bla</i> <sub>NDM-1</sub>	25	29.1% (CRAB)

13 isolates. Among the 47 STs identified, we reported 18 novel STs, which were submitted to the PubMLST database and assigned new STs (S1 Table). STs 451 (13.4%), 447 (7.2%), 195 (6.1%) and 848 (5.1%) were most common STs in this study. Four new alleles (*cpn60*-89, *gpi* 282, *rpoD* 117 & *rpoD* 118) were also assigned to 3 isolates of this study, which were submitted to PubMLST (<http://pubmlst.org/abaumannii/>).

A total of 47 STs were identified among 97 isolates, which were subjected to eBURST analysis and assigned into five clonal complexes (CC), three doubletons and thirteen singletons. CC1 contained 13 STs (42 isolates) and is largest CC with ST 451 founder ST, followed by the CC2 with 6 STs (13 isolates) with founder ST 447. CC3 and CC5 comprised of 3 STs with 8, 3 and 6 isolates respectively. To determine the clonal relationships of the STs obtained in this study, together with the 1489 STs in the global PubMLST *A. baumannii* database were clustered using the goeBURST (Fig. 1A). The resultant minimal spanning tree revealed that the 13 STs (represented by 43 isolates) are linked to the CC92 (Fig. 1B). CC92 is the largest CC among all the STs and represents the IC2. Three STs from this study ST 441, 491 and 231 comprising of eight isolates were linked to CC109, which belongs to the IC1. The 6 STs from this study ST 447, 585, 20, 391, 1389 and 1390 comprising 13 isolates from this study were linked to CC447, which represents IC8. Three STs with single isolates each from this study were linked to CC110, which represents IC 7. STs were also linked to the international clones and their respective clonal complex by Oxford and Pasteur MLST scheme (Table 3).



Majority of the CRAB isolates were linked to CC92 (45%) and CC447 (13%), which represented IC2 and IC8 respectively as reported previously (Diancourt et al., 2010). There were few isolates, which were linked to CC109 and CC110 and represented IC1 and IC7. None of the CSAB was linked to any clonal complex except ST 585, which was a part of CC442 (IC 8). STs and clonal complex for *bla*<sub>OXA-58</sub>-like and *bla*<sub>NDM-1</sub> were respectively highlighted in Table 2.

### 3.4. Genetic diversity and selection analysis

The sequence alignment of seven loci showed no insertion-deletion events. The length of the concatenated sequence of all seven loci is 2895 bp. The average GC content, the nucleotide diversity ( $\pi$ ), the number of polymorphic sites and ratio of non-synonymous ( $d_N$ ) to synonymous ( $d_S$ ) substitutions were determined for each MLST locus, and for the concatenated sequence of all seven loci of 97 isolates under study, and its mentioned in Table 4. The  $d_N/d_S$  values ranging from the 0.000 (*gltA*) to 0.028425 (*gpi*) indicate that all seven MLST loci exhibit purifying selection. The number of polymorphic sites varied from 9 for *cpn60* to 79 for the *gpi* and that for the concatenated sequence was 160. *Gpi* is the most polymorphic locus among the seven loci. The number of alleles ranged from 9 (*gltA*, *recA*, and *cpn60*) to 24 (*gpi*). The nucleotide diversity index ( $\pi$ ) was 0.01452 for concatenated sequences and ranged from 0.00155 (*gltA*) to 0.007893 (*gpi*) at different loci, suggesting the *gpi* locus is most diverse as compared to others.

### 3.5. Phylogenetic analysis

The concatenated sequences of all the 43 STs were used to build the phylogenetic tree by using the Maximum likelihood method and split



**Fig. 1.** Population snapshot. A) goeBURST analysis of ST 1489 present in the PubMLST database. The largest CC 92 is marked as red colored circles. B) Snapshot of CC 92. STs marked as red-colored circles are from the present study. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

**Table 2**  
STs positive for the *bla*<sub>OXA-58</sub>-like and *bla*<sub>NDM-1</sub> and respective clonal complex.

Resistance gene	STs	Clonal complex
<i>bla</i> <sub>OXA-58</sub> -like	930	
	1089	
<i>bla</i> <sub>NDM-1</sub>	1053	2
	441.	1
	862	
	391	8
	865	
	539	2
	451	2
	930	
	1089	

network analysis. The phylogenetic tree revealed that there were two major and one minor but distinct lineage, termed as L1, L2 & L3. The branches of the three lineages showed low bootstrap values suggesting the possible existence of homologous recombination (Fig. 2A). In addition, the split graph of 47 STs also revealed that three distinct subgroups corresponded to that of L1 to L3 (Fig. 2B).

3.6. Recombination and linkage disequilibrium analysis

*Phi* test is an efficient statistical test for the recombination. The *P*-value determined by the *Phi* test for 47 STs (whole population) and individual lineage were < 0.05 except L3, which had *P*-value of 0.2402. The split network analysis of 47 STs (Fig. 2B) showed lineage

**Table 3**  
STs linked to the International Clones along with respective clonal complex assigned by Oxford and Pasteur MLST scheme.

STs	IC	CC Oxford	CC Pasteur
208,863,539,1050,395,859,195,1050,1052,844,864,502,451,848	2	92	2
441, 491, 231	1	109	1
447, 585, 20, 391, 1389, 1390	8	447	157
993,1387,1388	7	110	25

L1 and L2 as a parallelogram-shaped very complex network structure, which was absent in the L3. L1 and L2 displayed a very complex inter-connecting network structure, however, merely visualized intersections were observed between L1 and L2 with L3. Further split network graphs of the seven individual loci revealed that the *gyrB* and *gpi* showed a network like parallelogram structures (S1Fig.), however, the split graphs of *gltA*, *gdhB*, *recA*, *cpn60* and *rpoD* genes were tree-like structures.

The mean per-site recombination/mutation ratio ( $\rho/\theta$ ) values were 13.35, 4.98, 0.95 and 0.20 for the whole population, L1, L2, and L3 respectively (Table 5). Standard association of index ( $I_A^S$ ) showed the homologous recombination by calculating the linkage disequilibrium among loci. Analysis of 47 STs understudy yielded  $I_A^S$  of 0.2838 ( $P = 1.00E-04$ ) and 0.2433 ( $P = 1.00E-04$ ), 0.3688 ( $P = 1.00E-04$ ) and 0.2805 ( $P = 7.00E-04$ ) for individual lineages L1, L2 and L3 respectively.

4. Discussion

Carbapenem-resistant *A. baumannii* (CRAB) has been deemed a critical-priority pathogen by the World Health Organization (Tacconelli et al., 2018). This study revealed that *bla*<sub>OXA-23</sub>-like is the major mechanism responsible for the carbapenem resistance phenotype as has been described in earlier studies (Fu et al., 2010; He et al., 2011; Ji et al., 2013; Wang et al., 2013). First time in India, we have detected three isolates positive for *bla*<sub>OXA-58</sub>-like. *bla*<sub>OXA-58</sub>-like is a plasmid-borne gene first traced in France in 2003 (Poirel et al., 2005) and later spread worldwide (Cameranesi et al., 2018; Ramoul et al., 2016).

**Table 4**  
Nucleotide and allelic diversity among seven MLST loci.

Locus	Length (bp)	Average G + C content (%)	No. of alleles	No. of polymorphic sites	Average dN/dS ratio	Nucleotide diversity( $\pi$ )
<i>gltA</i>	484	41.1	9	8	0	0.00155
<i>gyrB</i>	457	41.6	14	22	0.014189	0.01000
<i>gdhB</i>	344	36.6	11	21	0.070168	0.01418
<i>recA</i>	371	43.6	9	11	0	0.00665
<i>cpn60</i>	421	37.1	9	9	0.000368	0.00392
<i>gpi</i>	305	41.4	24	79	0.028425	0.007893
<i>rpoD</i>	513	39.1	12	10	0.006438	0.00336
All (47STs)	2895	40	46	160	1.752635	0.01452

Although there are several reports of *bla*<sub>NDM-1</sub> alone positive *A. baumannii* from India (Pragasam et al., 2016; Rahman et al., 2018), however, our study revealed an increasing incidence of CRAB isolates with *bla*<sub>NDM-1</sub> gene, which were also positive for *bla*<sub>OXA-23</sub>-like or *bla*<sub>OXA-58</sub>-like. There are reports of coexistence of *bla*<sub>OXA-23</sub>-like or *bla*<sub>OXA-58</sub>-like with *bla*<sub>NDM-1</sub>, synergistically which gave a very broad resistance profile (Krizova et al., 2012; Ramoul et al., 2016). However, we did not observe the high level of resistance profile in isolates of *bla*<sub>OXA-23</sub>-like or *bla*<sub>OXA-58</sub>-like with *bla*<sub>NDM-1</sub> positive isolates. This may be due to the lack of promoter for *bla*<sub>OXA-23</sub>-like or *bla*<sub>OXA-58</sub>-like or involvement of some other genetic regulatory mechanism (Hadjadj et al., 2018). The co-occurrence of *bla*<sub>NDM-1</sub> with active *bla*<sub>OXA-23</sub>-like or *bla*<sub>OXA-58</sub>-like in CRAB was a matter of concern as this will limit future therapeutic options (Zhou et al., 2015). Although the co-occurrence of *bla*<sub>NDM-1</sub> and *bla*<sub>OXA-23</sub>-like was earlier reported from India, this is the first report of the co-occurrence of *bla*<sub>NDM-1</sub> with *bla*<sub>OXA-58</sub>-like from India (Karthikeyan et al., 2010; Rahman et al., 2018). It was noticed that three STs of *bla*<sub>NDM-1</sub> harboring strains were found belonging to CC 2 but no similarity was seen in *bla*<sub>OXA-58</sub>-like. Interestingly, ST 1089 was shared by both of the *bla*<sub>OXA-58</sub>-like & *bla*<sub>NDM-1</sub> (Table 2). The other class-D beta-lactamase, the *bla*<sub>OXA-24</sub>-like gene was first identified in 1997, followed by several reports of the outbreak of *A. baumannii* harboring *bla*<sub>OXA-24</sub>-like gene (Bou et al., 2000) but none of the *A. baumannii* isolates was found to harbor *bla*<sub>OXA-24</sub>-like in this study. This study also showed the absence of *bla*<sub>VIM-2</sub> and *bla*<sub>IMP-1</sub> in all the isolates under study.

Currently, WGS and SNPs analysis methods are considered as the most discriminative typing methods but MLST is still very much accepted and employed due to its inter-laboratory reproducibility. MLST revealed diversity in the population under study both by number and novelty as 47 STs were represented by all 97 isolates, out of which 28 (59.6%) were novel STs that were assigned to 41 isolates. Majority of the CRAB isolates under study belonged to IC2. There have been many reports of *bla*<sub>OXA-23</sub>-like belonging to globally disseminated IC2 (Chen et al., 2017; Pagano et al., 2015; Potron et al., 2015; Zarrilli et al., 2012; Zarrilli et al., 2013). IC2 has already been designated as a pandemic lineage in Asia, North America and Europe (Adams-Haduch et al., 2011; Asai et al., 2011; Tan et al., 2013). Interestingly, in the South or Latin America, the predominant *A. baumannii* lineages reported so far were different from those reported in rest of the world, as the most prevalent ICs are IC5 (CC79<sup>Pas</sup>) and IC7 (CC25<sup>Pas</sup>) (Higgins et al., 2010; Opazo-Capurro et al., 2019). There are recent reports that suggested an

increased prevalence of IC2 in South America (Levy-Blitchtein et al., 2018; Vasconcellos et al., 2017). Apart from IC2, isolates from our study also belonged to IC1, IC7, and IC8. There are reports of IC2 isolates from India but this is the first time that we described the prevalence of IC1, IC7, and IC8 in Indian hospital settings. This underpins the hospital-wide spread of the international clones of CRAB. Presence of isolates belonging to IC8 and IC7 suggested the dissemination of CRAB, which differs from dominated IC1–3 in the Indian hospitals. We would also like to highlight that the majority of the STs, which were positive for the *bla*<sub>NDM-1</sub> belonged to the IC2 (Table 2).


The phylogenetic analysis using ML phylogenetic tree and split network analysis revealed three diverse lineages, majority of isolates belonged to lineage L1 along with the prevalence of the minor lineage L2 and L3 among the isolates from Indian hospitals. Further recombination analysis using *phi* test and split network analysis suggested significant evidence of recombination across the whole population level and within lineages L1 and L2. The split network analysis of the whole population indicated that inter-lineage recombination between the L1 and L2 lineages indicating an ongoing evolution. The split tree analysis on the individual MLST loci *gyrB* and *gpi* displayed intergenic recombination had occurred during the evolutionary history of these genes. However, *gltA*, *gdhB*, *recA*, *cpn60*, and *rpoD* gene loci do not have a sign of intergenic recombination, which suggested that the descent of these genes were clonal. The mean per-site recombination/mutation ratio ( $\rho/\theta$ ) values suggested that the recombination events occurred more frequently in the whole population level and point mutations were more prominent in L2 and L3. Linkage equilibrium analysis suggested that although the recombination played an important role in generating the genotypic diversity that was not enough to break down the clonal relationship, which indicated the clonal nature of the population. This suggested that the natural barriers were presented to prevent gene flow across lineages.

## 5. Conclusion

This is the first study of its kind to describe the epidemiology and genetic recombination of a large number of CRAB isolates from India. The *bla*<sub>OXA-23</sub>-like and *bla*<sub>NDM-1</sub> are observed as major carbapenem resistance determinants in the CRAB isolates. Isolates of this study were found to be representative of the global diversity of the clinically important CRAB, where maximum isolates are linked to the international spread clones. More studies with isolates from different parts of India

**Table 5**  
Results of recombination tests among the whole population and different lineages of population.

Population(n)	<i>Phi</i> test	Recombination analysis				Linkage disequilibrium		
		Theta/site	Rho/site	Rho/theta	LB 95%	UB 95%	$I_A^S$	P value
All (n = 47STs)	0.0	1.015E-02	0.135529	13.357	6.909E-02	0.293E-03	0.2838	< 1.00E-04
L1 (n = 29STs)	0.0	1.013E-02	5.053E-02	4.989	2.913E-02	9.467E-02	0.2433	< 1.00E-04
L2 (n = 12STs)	1.356E-9	5.494E-03	5.497E-03	0.9573	3.75E-03	7.96E-03	0.3688	< 1.00E-04
L3 (n = 6STs)	0.2402	5.698E-03	1.182E-03	0.2074	7.712E-04	1.573E-03	0.2805	7.0E-04



**Fig. 2.** Phylogenetic analysis. A) Phylogenetic tree generated from concatenated sequences of the MLST allelic loci with maximum likelihood method using MEGA 6.1. Three lineages L1, L2, and L3 are marked. B) Split network analysis of 47 STs from the present study and based on the concatenated sequences of seven MLST loci. The numbering in the figure refers to ST. Three subgroups corresponding to lineage L1, L2 and L3 are marked.

are recommended to understand the nationwide epidemiology of this bug. Further, Whole Genome Sequencing of this collection of CRAB isolates will give major insights into the genetic diversity, resistance, mobile genetic elements and virulence determinants of the CRAB from India.

#### Declaration of Competing Interest

None.

#### Acknowledgments

We acknowledge the funding from Department of Biotechnology (Government of India) Project No. (BT/PR8596/MED/29/765/2013) to VG and Council for Scientific and Industrial Research (CSIR) Project (MLP 0016GEAR) to PBP. Sunil Kumar and Prashant P. Patil were supported by fellowships from the Department of Biotechnology and University Grant Commission (Government of India) respectively.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.megid.2019.103986>.

#### References

- Adams, M.D., Goglin, K., Molyneux, N., Hujer, K.M., Lavender, H., Jamison, J.J., MacDonald, I.J., Martin, K.M., Russo, T., Campagnari, A.A., Hujer, A.M., Bonomo, R.A., Gill, S.R., 2008. Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J. Bacteriol.* 190, 8053–8064.
- Adams-Haduch, J.M., Onuoha, E.O., Bogdanovich, T., Tian, G.B., Marschall, J., Urban, C.M., Spellberg, B.J., Rhee, D., Halstead, D.C., Pasculle, A.W., Doi, Y., 2011. Molecular epidemiology of carbapenem-nonsusceptible *Acinetobacter baumannii* in the United States. *J. Clin. Microbiol.* 49, 3849–3854.
- Asai, S., Umezawa, K., Iwashita, H., Ohshima, T., Ohashi, M., Sasaki, M., Hayashi, H., Matsui, M., Shibayama, K., Inokuchi, S., Miyachi, H., 2011. An outbreak of blaOXA-51-like- and blaOXA-66-positive *Acinetobacter baumannii* ST208 in the emergency intensive care unit. *J. Med. Microbiol.* 63, 1517–1523.
- Auton, A., McVean, G., 2007. Recombination rate estimation in the presence of hotspots. *Genome Res.* 17, 1219–1227.
- Bartual, S.G., Seifert, H., Hippler, C., Luzon, M.A., Wisplinghoff, H., Rodriguez-Valera, F., 2005. Development of a multilocus sequence typing scheme for characterization of clinical isolates of *Acinetobacter baumannii*. *J. Clin. Microbiol.* 43, 4382–4390.
- Bou, G., Oliver, A., Martinez-Beltran, J., 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob. Agents Chemother.* 44, 1556–1561.
- Brown, S., Young, H.K., Amey, S.G., 2005. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clin. Microbiol. Infect.* 11, 15–23.
- Bruen, T.C., Philippe, H., Bryant, D., 2006. A simple and robust statistical test for detecting the presence of recombination. *Genetics* 172, 2665–2681.
- Bryant, D., Moulton, V., 2004. Neighbor-net: an agglomerative method for the construction of phylogenetic networks. *Mol. Biol. Evol.* 21, 255–265.
- Cameranesi, M.M., Moran-Barrio, J., Limansky, A.S., Repizo, G.D., Viale, A.M., 2018. Site-specific recombination at XerC/D sites mediates the formation and resolution of

- plasmid co-integrates carrying a blaOXA-58- and TnpA6-resistance module in *Acinetobacter baumannii*. *Front. Microbiol.* 9, 66.
- Chen, Y., Gao, J., Zhang, H., Ying, C., 2017. Spread of the blaOXA-23-containing Tn2008 in carbapenem-resistant *Acinetobacter baumannii* isolates grouped in CC92 from China. *Front. Microbiol.* 8, 163.
- Diancourt, L., Passet, V., Nemeč, A., Dijkshoorn, L., Brisse, S., 2010. The population structure of *Acinetobacter baumannii*: expanding multidresistant clones from an ancestral susceptible genetic pool. *PLoS One* 5, e10034.
- Dijkshoorn, L., Nemeč, A., Seifert, H., 2007. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat. Rev. Microbiol.* 5, 939–951.
- Doi, Y., Husain, S., Potoski, B.A., McCurry, K.R., Paterson, D.L., 2009. Extensively drug-resistant *Acinetobacter baumannii*. *Emerg. Infect. Dis.* 15, 980–982.
- Feil, E.J., Li, B.C., Aanensen, D.M., Hanage, W.P., Spratt, B.G., 2004. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. *J. Bacteriol.* 186, 1518–1530.
- Fournier, P.E., Vallet, D., Barbe, V., Audic, S., Ogata, H., Poirel, L., Richet, H., Robert, C., Mangelot, S., Abergel, C., Nordmann, P., Weissenbach, J., Raoult, D., Claverie, J.M., 2006. Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. *PLoS Genet.* 2, e7.
- Francisco, A.P., Bugalho, M., Ramirez, M., Carriço, J.A., 2009. Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach. *BMC Bioinform.* 10, 152.
- Fu, Y., Zhou, J., Zhou, H., Yang, Q., Wei, Z., Yu, Y., Li, L., 2010. Wide dissemination of OXA-23-producing carbapenem-resistant *Acinetobacter baumannii* clonal complex 22 in multiple cities of China. *J. Antimicrob. Chemother.* 65, 644–650.
- Grisold, A.J., Zarfel, G., Strenger, V., Feierl, G., Leitner, E., Masoud, L., Hoenigl, M., Raggam, R.B., Dosch, V., Marth, E., 2010. Use of automated repetitive-sequence-based PCR for rapid laboratory confirmation of nosocomial outbreaks. *J. Inf. Secur.* 60, 44–51.
- Hadjadj, L., Bakour, S., Rolain, J.M., 2018. Co-occurrence of carbapenemase encoding genes in *Acinetobacter baumannii*, a dream or reality? *BMC Microbiol.* 18, 107.
- Hamouda, A., Evans, B.A., Townner, K.J., Amyes, S.G., 2010. Characterization of epidemiologically unrelated *Acinetobacter baumannii* isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of bla(OXA-51-like) genes. *J. Clin. Microbiol.* 48, 2476–2483.
- Haubold, B., Hudson, R.R., 2000. LIAN 3.0: detecting linkage disequilibrium in multilocus data. *Bioinformatics* 16, 847–849.
- He, C., Xie, Y., Fan, H., Kang, M., Tao, C., Zhang, R., Hu, Y., Chen, Z., Wang, L., 2011. Spread of imipenem-resistant *Acinetobacter baumannii* of European clone II in Western China. *Int. J. Antimicrob. Agents* 38, 257–260.
- Higgins, P.G., Wisplinghoff, H., Krut, O., Seifert, H., 2007. A PCR-based method to differentiate between *Acinetobacter baumannii* and *Acinetobacter genomic species* 13TU. *Clin. Microbiol. Infect.* 13, 1199–1201.
- Higgins, P.G., Dammhayn, C., Hackel, M., Seifert, H., 2010. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J. Antimicrob. Chemother.* 65, 233–238.
- Howard, A., O'Donoghue, M., Feeney, A., Sleator, R.D., 2012. *Acinetobacter baumannii*: an emerging opportunistic pathogen. *Virulence* 3, 243–250.
- Huson, D.H., Bryant, D., 2005. Application of phylogenetic networks in evolutionary studies. *Mol. Biol. Evol.* 23, 254–267.
- Ji, S., Chen, Y., Ruan, Z., Fu, Y., Ji, J., Fu, Y., Wang, H., Yu, Y., 2013. Prevalence of carbapenem-hydrolyzing class D beta-lactamase genes in *Acinetobacter* spp. isolates in China. *Eur. J. Clin. Microbiol. Infect. Dis.* 33, 989–997.
- Karthikeyan, K., Thirumarayan, M.A., Krishnan, P., 2010. Coexistence of blaOXA-23 with blaNDM-1 and arma in clinical isolates of *Acinetobacter baumannii* from India. *J. Antimicrob. Chemother.* 65, 2253–2254.
- Kayama, S., Shigemoto, N., Shimizu, W., Kuwahara, R., Ikeda, M., Ikebe, K., Maeda, K., Hisatsune, J., Ohge, H., Sugai, M., 2014. Tripoli metallo-beta-lactamase-1 (TMB-1)-producing *Acinetobacter* spp. with decreased resistance to imipenem in Japan. *Antimicrob. Agents Chemother.* 58, 2477–2478.
- Krizova, L., Bonnin, R.A., Nordmann, P., Nemeč, A., Poirel, L., 2012. Characterization of a multidrug-resistant *Acinetobacter baumannii* strain carrying the blaNDM-1 and blaOXA-23 carbapenemase genes from the Czech Republic. *J. Antimicrob. Chemother.* 67, 1550–1552.
- Lee, N.Y., Lee, H.C., Ko, N.Y., Chang, C.M., Shih, H.I., Wu, C.J., Ko, W.C., 2007. Clinical and economic impact of multidrug resistance in nosocomial *Acinetobacter baumannii* bacteremia. *Infect. Control Hosp. Epidemiol.* 28, 713–719.
- Levy-Blihtchein, S., Roca, I., Plasencia-Rebata, S., Vicente-Taboada, W., Velasquez-Pomar, J., Munoz, L., Moreno-Morales, J., Pons, M.J., Del Valle-Mendoza, J., Vila, J., 2018. Emergence and spread of carbapenem-resistant *Acinetobacter baumannii* international clones II and III in Lima, Peru. *Emerg. Microbes Infect.* 7, 119.
- Librado, P., Rozas, J., 2009. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. *Bioinformatics* 25, 1451–1452.
- Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice, L.B., Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T., Monnet, D.L., 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 18, 268–281.
- Martin, D.P., Murrell, B., Golden, M., Khoo, A., Muhire, B., 2015. RDP4: detection and analysis of recombination patterns in virus genomes. *Virus Evol.* 1.
- Nigro, S.J., Hall, R.M., 2012. Tn6167, an antibiotic resistance island in an Australian carbapenem-resistant *Acinetobacter baumannii* GC2, ST92 isolate. *J. Antimicrob. Chemother.* 67, 1342–1346.
- Nurtop, E., Bayindir Bilman, F., Menekse, S., Kurt Azap, O., Gonen, M., Ergonul, O., Can, F., 2019. Promoters of colistin resistance in *Acinetobacter baumannii* infections. *Microb. Drug Resist.*
- Opazo-Capurro, A., San Martin, I., Quezada-Aguiluz, M., Morales-Leon, F., Dominguez-Yevenes, M., Lima, C.A., Esposito, F., Cerdeira, L., Bello-Toledo, H., Lincopan, N., Gonzalez-Rocha, G., 2019. Evolutionary dynamics of carbapenem-resistant *Acinetobacter baumannii* circulating in Chilean hospitals. *Infect. Genet. Evol.* 73, 93–97.
- Pagano, M., Barin, J., Martins, A.F., Zavascki, A.P., 2015. High endemic rates of OXA-23-producing carbapenem-resistant *Acinetobacter baumannii* isolates caused by the persistence of major clones in hospitals in a Brazilian city 5 years after an outbreak. *Infect. Control Hosp. Epidemiol.* 36, 860–862.
- Paton, R., Miles, R.S., Hood, J., Amyes, S.G., 1993. ARI 1: beta-lactamase-mediated imipenem resistance in *Acinetobacter baumannii*. *Int. J. Antimicrob. Agents* 2, 81–87.
- Peleg, A.Y., Adams, J., Paterson, D.L., 2007a. Tigecycline efflux as a mechanism for nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 51, 2065–2069.
- Peleg, A.Y., Potoski, B.A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E.J., Bhat, S.V., Paterson, D.L., 2007b. *Acinetobacter baumannii* bloodstream infection while receiving tigecycline: a cautionary report. *J. Antimicrob. Chemother.* 59, 128–131.
- Peleg, A.Y., Seifert, H., Paterson, D.L., 2008. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin. Microbiol. Rev.* 21, 538–582.
- Perez, F., Hujer, A.M., Hujer, K.M., Decker, B.K., Rather, P.N., Bonomo, R.A., 2007. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 51, 3471–3484.
- Poirel, L., Nordmann, P., 2006. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin. Microbiol. Infect.* 12, 826–836.
- Poirel, L., Marque, S., Heritier, C., Segonds, C., Chabanon, G., Nordmann, P., 2005. OXA-58, a novel class D (beta)-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 49, 202–208.
- Poirel, L., Naas, T., Nordmann, P., 2010. Diversity, epidemiology, and genetics of class D beta-lactamases. *Antimicrob. Agents Chemother.* 54, 24–38.
- Potron, A., Poirel, L., Nordmann, P., 2015. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: mechanisms and epidemiology. *Int. J. Antimicrob. Agents* 45, 568–585.
- Pourcel, C., Minandri, F., Hauck, Y., D'Arezzo, S., Imperi, F., Vergnaud, G., Visca, P., 2011. Identification of variable-number tandem-repeat (VNTR) sequences in *Acinetobacter baumannii* and interlaboratory validation of an optimized multiple-locus VNTR analysis typing scheme. *J. Clin. Microbiol.* 49, 539–548.
- Pragasam, A.K., Vijayakumar, S., Bakthavatchalam, Y.D., Kapil, A., Das, B.K., Ray, P., Gautam, V., Sistla, S., Parija, S.C., Walia, K., Ohri, V.C., Anandan, S., Veerarraghavan, B., 2016. Molecular characterisation of antimicrobial resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* during 2014 and 2015 collected across India. *Indian J. Med. Microbiol.* 34, 433–441.
- Rafei, R., Pailhories, H., Hamze, M., Eveillard, M., Mallat, H., Dabboussi, F., Joly-Guillou, M.L., Kempf, M., 2015. Molecular epidemiology of *Acinetobacter baumannii* in different hospitals in Tripoli, Lebanon using bla(OXA-51-like) sequence based typing. *BMC Microbiol.* 15, 103.
- Rahman, M., Prasad, K.N., Gupta, S., Singh, S., Singh, A., Pathak, A., Gupta, K.K., Ahmad, S., Gonzalez-Zorn, B., 2018. Prevalence and molecular characterization of New Delhi metallo-beta-lactamases in multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from India. *Microb. Drug Resist.* 24, 792–798.
- Ramoul, A., Loucif, L., Bakour, S., Amiri, S., Dekhil, M., Rolain, J.M., 2016. Co-occurrence of blaNDM-1 with blaOXA-23 or blaOXA-58 in clinical multidrug-resistant *Acinetobacter baumannii* isolates in Algeria. *J. Glob. Antimicrob. Resist.* 6, 136–141.
- Robledo, I.E., Aquino, E.E., Sante, M.I., Santana, J.L., Otero, D.M., Leon, C.F., Vazquez, G.J., 2010. Detection of KPC in *Acinetobacter* spp. in Puerto Rico. *Antimicrob. Agents Chemother.* 54, 1354–1357.
- Robledo, I.E., Aquino, E.E., Vazquez, G.J., 2011. Detection of the KPC gene in *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* during a PCR-based nosocomial surveillance study in Puerto Rico. *Antimicrob. Agents Chemother.* 55, 2968–2970.
- Rynga, D., Shariff, M., Deb, M., 2013. Multi-locus sequence types of *Acinetobacter baumannii* clinical isolates from India. *J. Infect. Dev. Ctries* 7, 358–360.
- Saranathan, R., Vasanth, V., Vasanth, T., Shabareesh, P.R., Shashikala, P., Devi, C.S., Kalaivani, R., Asir, J., Sudhakar, P., Prashanth, K., 2015. Emergence of carbapenem non-susceptible multidrug resistant *Acinetobacter baumannii* strains of clonal complexes 103(B) and 92(B) harboring OXA-type carbapenemases and metallo-beta-lactamases in Southern India. *Microbiol. Immunol.* 59, 277–284.
- Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavalieri, M., Cox, E.M., Houchens, C.R., Grayson, M.L., Hansen, P., Singh, N., Theuretzbacher, U., Magrini, N., 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* 18, 318–327.
- Tamura, K., Stecher, G., Peterson, D., Filipi, A., Kumar, S., 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* 30, 2725–2729.
- Tan, S.Y., Chua, S.L., Liu, Y., Hoiby, N., Andersen, L.P., Givskov, M., Song, Z., Yang, L., 2013. Comparative genomic analysis of rapid evolution of an extreme-drug-resistant *Acinetobacter baumannii* clone. *Genome Biol. Evol.* 5, 807–818.
- Tiwari, V., Kapil, A., Moganty, R.R., 2012. Carbapenem-hydrolyzing oxacillinase in high resistant strains of *Acinetobacter baumannii* isolated from India. *Microb. Pathog.* 53, 81–86.
- Turton, J.F., Matos, J., Kaufmann, M.E., Pitt, T.L., 2009. Variable number tandem repeat loci providing discrimination within widespread genotypes of *Acinetobacter baumannii*. *Eur. J. Clin. Microbiol. Infect. Dis.* 28, 499–507.
- Vasconcellos, F.M., Tiba-Casas, M.R., Tavares, L.C.B., Souza, W.V., Garcia, D.O.,

- Camargo, C.H., 2017. Evaluation of a new trilocus sequence-based multiplex-PCR to detect major *Acinetobacter baumannii* clonal complexes circulating in Brazil. *Infect. Genet. Evol.* 54, 4–6.
- Wang, X., Qiao, F., Yu, R., Gao, Y., Zong, Z., 2013. Clonal diversity of *Acinetobacter baumannii* clinical isolates revealed by a snapshot study. *BMC Microbiol.* 13, 234.
- Zarrilli, R., Di Popolo, A., Bagattini, M., Giannouli, M., Martino, D., Barchitta, M., Quattrocchi, A., Iula, V.D., de Luca, C., Scarcella, A., Triassi, M., Agodi, A., 2012. Clonal spread and patient risk factors for acquisition of extensively drug-resistant *Acinetobacter baumannii* in a neonatal intensive care unit in Italy. *J. Hosp. Infect.* 82, 260–265.
- Zarrilli, R., Pournaras, S., Giannouli, M., Tsakris, A., 2013. Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages. *Int. J. Antimicrob. Agents* 41, 11–19.
- Zhou, S., Chen, X., Meng, X., Zhang, G., Wang, J., Zhou, D., Guo, X., 2015. "Roar" of blaNDM-1 and "silence" of blaOXA-58 co-exist in *Acinetobacter pittii*. *Sci. Rep.* 5, 8976.